viewZelira Therapeutics Ltd

Zelira Therapeutics launches HOPE™ autism products in Australia through TGA Special Access Scheme

The products consist of two pharmaceutical-grade proprietary formulations developed to target Autism Spectrum Disorder as a disease indication.

Zelira Therapeutics Ltd - Zelira Therapeutics launches Hope Autism products in Australia through the TGA Special Access Scheme
HOPE™ is part of Zelira’s family of revenue generating medicinal cannabis formulations

Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCQB: ZLDAF) (FRA:G1G) proprietary cannabinoid medicines, HOPE 1™ and HOPE 2™, are now available by prescription to patients in Australia through the Therapeutic Goods Administration’s (TGA) Special Access Scheme and through authorised prescribers. 

The HOPE™ range of products will be distributed nationally via Health House Holdings. 

Key milestone

Zelira Therapeutics managing director ex-USA Dr Richard Hopkins said: “Following the success of the HOPE™ launches in Pennsylvania and Louisiana, we are excited to make these products available to patients and physicians in Australia.

“This represents another key milestone in our commitment to bring the benefits of HOPE™ to patients in global markets.

“We believe HOPE™ can help support the unmet needs of the ASD community in Australia and look forward to working with all stakeholders to ensure they can access the benefits that medicinal cannabis can provide.”

Targets Autism Spectrum Disorder

HOPE™ is part of Zelira’s family of revenue-generating medicinal cannabis formulations.

The products consist of two pharmaceutical-grade proprietary formulations developed to target Autism Spectrum Disorder (ASD) as a disease indication.

The HOPE™ (HOPE 1 & 2) products were launched under licence to Ilera Healthcare in Pennsylvania in 2019 with the support of HOPE Grows for Autism, a leading autism advocacy group based in Pennsylvania.

HOPE™ has since established itself as one of the top-selling formulated medicinal cannabis products in Ilera Healthcare’s portfolio.

In August 2020, HOPE™ was launched under license in Louisiana in partnership with Advanced Biomedics LLC.

Quick facts: Zelira Therapeutics Ltd

Price: 0.077 AUD

Market: ASX
Market Cap: $91.27 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...


Zelira Therapeutics sees 'multiple shots on goal' with a number of revenue...

Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) deputy chairman Harry Karelis speaks to Proactive's Andrew Scott soon after announcing a strategic consolidation of its operations which sees leadership of the company transfer to the US-based team, with Dr Oludare Odumosu assuming the...

23 hours ago

2 min read